Estimation of heritability of different outcomes for genetic studies of TNFi response in patients with rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 74, Issue 12, 2015, Pages 2183-2187

  Mirkov, Maša Umićević ^a   Janss, Luc ^b   Vermeulen, Sita H ^a   Van De Laar, Mart A F J ^c   Van Riel, Piet L C M ^a   Guchelaar, Henk Jan ^d   Brunner, Han G ^a   Albers, Cornelis A ^a   Coenen, Marieke J H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b AARHUS UNIVERSITY   (Denmark)

^c MEDISCH SPECTRUM TWENTE   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DNA; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; DAS28; DNA DETERMINATION; DRUG RESPONSE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HERITABILITY; HUMAN; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; VISUAL ANALOG SCALE; ADULT; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; METABOLISM; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DNA; FEMALE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84954242997     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-205541     Document Type: Article

References (24)

1. Maini RN, Breedveld FC, Kalden JR, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004;50:1051-65.
2. Smolen JS, Han C, Bala M, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005;52:1020-30.
3. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
4. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
5. Liu C, Batliwalla F, Li W, et al. Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol Med 2008;14:575-81.
6. Krintel SB, Palermo G, Johansen JS, et al. Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNFalpha inhibitors in patients with rheumatoid arthritis. Pharmacogenet Genomics 2012;22:577-89.
7. Umićević Mirkov M, Cui J, Vermeulen SH, et al. Genome-wide association analysis of anti-TNF drug response in rheumatoid arthritis patients. Ann Rheum Dis 2013;72:1375-81.
8. Plant D, Bowes J, Potter C, et al. Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum 2011;63:645-53.
9. Cui J, Stahl EA, Saevarsdottir S, et al. Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet 2013;9:e1003394.
10. van der Heijde DM, van 't Hof M, van Riel PL, et al. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993;20:579-81.
11. Prevoo ML, van 't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
12. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Rheum Dis Clin North Am 2009;35:745-57.
13. Janss L, de Los Campos G, Sheehan N, et al. Inferences from genomic models in stratified populations. Genetics 2012;192:693-704.
14. Yang J, Lee SH, Goddard ME, et al. GCTA: a tool for genome-wide complex trait analysis. Am J Hum Genet 2011;88:76-82.
15. Kievit W, Fransen J, Adang EM, et al. Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology 2011;50:196-203.
16. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Gen 2007;81:559-75.
17. Price AL, Patterson NJ, Plenge RM, et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat Gen 2006;38:904-9.
18. Sorensen LP, Janss L, Madsen P, et al. Estimation of (co)variances for genomic regions of flexible sizes: application to complex infectious udder diseases in dairy cattle. Genet Sel Evol 2012;44:18.
19. Speed D, Hemani G, Johnson MR, et al. Improved heritability estimation from genome-wide SNPs. Am J Hum Gen 2012;91:1011-21.
20. Ferreira MA, Purcell SM. A multivariate test of association. Bioinformatics 2009;25:132-3.
21. Umicevic Mirkov M, Coenen MJ. Pharmacogenetics of disease-modifying antirheumatic drugs in rheumatoid arthritis: towards personalized medicine. Pharmacogenomics 2013;14:425-44.
22. Plant D, Wilson AG, Barton A. Genetic and epigenetic predictors of responsivness to treatment in RA. Nat Rev Rheumatol 2014;10:329-37.
23. Wolfe F, Pincus T, Thompson AK, et al. The assessment of rheumatoid arthritis and the acceptability of self-report questionnaires in clinical practice. Arthritis Rheum 2003;49:59-63.
24. Bombardier C, Tugwell P, Sinclair A, et al. Preference for endpoint measures in clinical trials: results of structured workshops. J Rheumatology 1982;9:798-801.